Onderzoeksgraad Lintuzumab

Lintuzumabisahumanizedmonoclonalantibody, HuM195, thattargetsthecellsurfaceantigenCD33thatisexpressedonthevastmajorityofacutemyeloidleukemia (AML) cells.[225Ac]Ac-lintuzumabclinicaltrialswerediscussedindetailinreference.LintuzumabisunderinvestigationinclinicaltrialNCT00016159 (ChemotherapyPlusMonoclonalAntibodyinTreatingPatientsWithAcutePromyelocyticLeukemia) .

225Ac-lintuzumab, HuM195, SGN-33, SMARTM195, HuM195, CAS:166089-32-3

Mammalian Cells

MyeloidcellsurfaceantigenCD33, Sialicacid-bindingIg-likelectin3, Siglec-3, CD33, gp67, SIGLEC3

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Protein A/G purified from cell culture supernatant.

1.39mg/ml

Please contact with the lab for this information.

>95% as determined by SDS-PAGE.

Liquid

0.01M PBS, pH7.4.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at4°C short term (1-2weeks) . Store at-20°C 12 months. Store at -191°C long term.

For research use only. Not suitable for clinical or therapeutic use.

0.01M PBS, pH7.4.

Human

IgG1-kappa